ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1279

Cerebrovascular Accidents in Pediatric and Adult Systemic Lupus Erythematosus: A Comparison of Epidemiology and Outcomes

Ekemini Ogbu1, Jareen Meinzen-Derr2, Michael Wagner2, Rashmi Sahay2, Dhriti Sharma2, J Michael Taylor2, Sudhakar Vadivelu3, Mekibib Altaye2 and hermine brunner1, 1Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, 2Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 3University of Cincinnati College of Medicine, Cincinnati, OH

Meeting: ACR Convergence 2024

Keywords: Brain, Pediatric rheumatology, Stroke, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 17, 2024

Title: Pediatric Rheumatology – Clinical Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Cerebrovascular accidents (CVA) are one of the most devastating neurologic manifestations of childhood-onset systemic lupus erythematosus (cSLE).  The spectrum of CVA in cSLE (CVAcSLE) includes thromboembolic, ischemic, and hemorrhagic events. Despite the severity and potentially disabling effects of CVA, large epidemiologic studies are lacking. Studies of adult-onset systemic lupus erythematosus (aSLE) suggest higher CVA severity and poorer outcomes with aSLE compared to other adults with CVA. Comparative studies on CVA in aSLE and cSLE are lacking. Thus, the purpose of this study was to understand the epidemiology of CVAcSLE, and compare CVA outcomes between cSLE and aSLE.

Methods: This retrospective cohort study utilized de-identified data over a 20-year period from an international federated real-world patient database (TriNetX). We included all patients with ICD-9 and/or ICD-10 codes corresponding to SLE. The TriNetX database automatically excludes patients greater than 90 years old to maintain confidentiality of the patients. We defined cSLE and aSLE as patients aged ≤ 18 years and ≥ 19 years respectively at the first recorded ICD code corresponding to SLE. We defined CVA as the presence of ICD-9 and/or ICD-10 codes corresponding to transient ischemic attack and/or CVA.

Results: Of the 112, 081, 954 patients in the TriNetX cohort, 21803 (0.02%) patients had SLE. Most patients with SLE were female (86%), White (66%) and non-Hispanic (89%) (Table 1). The prevalence of SLE was highest in the United States South compared to other regions (Table 1). The prevalence of CVA was 19% (n = 4123) in SLE patients overall, 8% (n = 30) in cSLE and 19% (n = 4093) in aSLE. In both cSLE and aSLE, the prevalence of CVA was highest in White patients followed by Black and other races; and also higher in non-Hispanic versus Hispanic patients. There was no significant difference in CVA prevalence by sex in both cSLE and aSLE. The odds of having CVA in aSLE was higher than in cSLE [OR 2.90; 95% CI (2.00, 4.21)]. The significantly higher risk in aSLE versus cSLE remained even after adjusting for age, sex, and race [OR 2.19; 95% CI (1.42 – 3.37)]. The risk of CVA was higher in females versus males [OR 1.16; 95% CI (1.05, 1.29)]. There was no significant difference in the 90-day readmission rate following CVA in cSLE compared to aSLE.

Conclusion: cSLE is associated with a high risk of CVA as 1 out of 12 children with cSLE will develop a CVA. Given that aSLE patients with CVA have a higher risk of CVA recurrence, and poorer outcomes compared to other non-SLE adults with CVA, further studies are needed on CVA risk factors and longer-term outcomes in cSLE.

Supporting image 1

Table 1: Comparison of Study Cohort Characteristics


Disclosures: E. Ogbu: None; J. Meinzen-Derr: None; M. Wagner: None; R. Sahay: None; D. Sharma: None; J. Taylor: None; S. Vadivelu: None; M. Altaye: None; h. brunner: AbbVie/Abbott, 2, AstraZeneca-Medimmune, 2, Biogen, 2, Boehringer-Ingelheim, 2, Bristol-Myers Squibb, 2, 12, Contributions, Celgene, 2, Eli Lilly, 2, 12, Contributions, EMD Serono, 2, F. Hoffmann-La Roche, 2, 12, Contributions, GlaxoSmithKlein(GSK), 2, 6, 12, Contributions, Janssen, 2, 12, Contributions, Merck/MSD, 2, Novartis, 2, 6, 12, Contributions, Pfizer, 2, 12, Contributions, Roche, 6, R-Pharm, 2, Sanofi, 2, UCB, 2.

To cite this abstract in AMA style:

Ogbu E, Meinzen-Derr J, Wagner M, Sahay R, Sharma D, Taylor J, Vadivelu S, Altaye M, brunner h. Cerebrovascular Accidents in Pediatric and Adult Systemic Lupus Erythematosus: A Comparison of Epidemiology and Outcomes [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/cerebrovascular-accidents-in-pediatric-and-adult-systemic-lupus-erythematosus-a-comparison-of-epidemiology-and-outcomes/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cerebrovascular-accidents-in-pediatric-and-adult-systemic-lupus-erythematosus-a-comparison-of-epidemiology-and-outcomes/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology